VJOncology is committed to improving our service to you

ESMO 2017 | What is the best treatment for RAS wild-type metastatic colorectal cancer?

VJOncology is committed to improving our service to you

Alfredo Carrato

Alfredo Carrato, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, describes interesting trials discussed at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. An interesting trial presented this year investigated FOLFOXIRI plus panitumumab (NCT01358812). It found a high response rate in patients with RAS wild-type metastatic colorectal cancer. Another interesting trial investigated whether to add an EGFR inhibitor after treatment with bevacizumab in RAS wild-type colorectal cancer showed that bevacizumab conferred an improvement in progression free survival.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter